Metabolic Dysfunction-Associated Steatotic Liver Disease: Current Treatment Strategies and Novel Therapies Authors: Anoushka Shenoy, Aijaz Ahmed, Donghee Kim Published: 2026 ABSTRACT Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as a challenging multi-system global health problem, affecting approximately one-third of the world’s population. Lifestyle modifications remain the cornerstone of MASLD management, which poses challenges in this population. The recent US Food and Drug Administration approval of resmetirom and semaglutide for the treatment of metabolic dysfunction-associated steatohepatitis with fibrosis signifies a substantial transformation in the therapeutic landscape. Other new therapeutic options are emerging, with encouraging phase 3 data from several agents spanning diverse mechanisms of action. This review summarizes the contemporary non-pharmacological and pharmacological approaches to MASLD. INTRODUCTION Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as nonalcoholic fatty liver disease (NAFLD), has emerged as the most prevalent chronic liver disease worldwide.1 MASLD is recognized as a major driver of liver-related and extrahepatic morbidity and mortality.2,3 The rapid rise in MASLD parallels the increase in obesity, type 2 diabetes mellitus (T2DM), and cardiometabolic disease. Current estimates indicate MASLD affects up to 38% of adults globally, with prevalence projected to increase to 55% by 2040.4 Population-based studies show that approximately 75% of individuals with obesity5 and 65% of individuals with T2DM6 have MASLD. MASLD is characterized by the accumulation of fat in >5% of hepatocytes with at least one concurrent cardiometabolic criterion. Approximately 20% to 30% of individuals with MASLD progress to metabolic dysfunction-associated steatohepatitis (MASH), characterized by hepatocellular injury and inflammation.7 Within this subset, 30% to 40% develop advanced fibrosis, and 20% may progress to cirrhosis.8 MASLD increases the risk of hepatocellular carcinoma (HCC) 8.6-fold, with annual HCC incidence rates of 0.8% to 2.3% in patients with MASH cirrhosis.9 MASH is now the leading cause of HCC among patients listed for liver transplantation in the United States (US).10 The COVID-19 (coronavirus disease 2019) pandemic has further amplified the burden of MASLD. Significant increases in advanced fibrosis among individuals with MASLD have been observed during the pandemic.11,12 Furthermore, MASLD increased the risk of adverse COVID-19 management challenges, intensive care unit admissions, and mortality during the COVID-19 pandemic.13-15 Despite the substantial global burden, therapeutic options and treatment recommendations for MASLD remain limited. Lifestyle modifications, including dietary restrictions, physical activity, and weight loss, alongside management of concomitant cardiometabolic diseases, remain the first-line treatment. Recently, in 2024, resmetirom, a selective thyroid hormone receptor-β (THR-β) agonist, became the first US Food and Drug Administration (FDA)-approved therapy for noncirrhotic MASH with fibrosis (F2–F3).16 In 2025, semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, was also approved for MASH with fibrosis (F2–F3).17 Other therapeutic agents may be approved in the near future. Drug development for MASH is advancing, with encouraging phase 3 data from several agents spanning diverse mechanisms of action. The purpose of this review article is to outline the current therapeutic landscape for MASLD, including lifestyle modifications and both FDA-approved and novel pharmacologic approaches, to provide an up-to-date review for its management (Fig. 1). Effective management integrates lifestyle modifications with additional pharmacologic therapies. Pharmacologic therapies are needed for patients who fail to develop a durable response to lifestyle modifications. LIFESTYLE MODIFICATION FOR THE TREATMENT OF MASLD 1. Weight reduction The obesity epidemic has paralleled the increasing burden of MASLD for the past few decades.18 In the US, MASLD prevalence increased from 29.5% to 40.3% from 1996 to 2016, with obesity rising from 30.5% to 41.9% during the same period.19,20 Obesity is a major driver in the development and progression of MASLD, with one meta-analysis finding the pooled prevalence of MASLD in overweight individuals to be 70% and in obese individuals 75%, and the prevalence of MASH to be 34% in both groups.5 Given the direct correlation between obesity and MASLD, weight loss remains the cornerstone in the management of MASLD. Evidence has consistently demonstrated a dose-dependent relationship between weight loss and disease regression. A prospective study of 293 patients with MASH found that the degree of weight loss was independently associated with histologic improvements. In patients who achieved ≥5% weight loss through lifestyle modifications, 58% experienced MASH resolution, and in those who lost ≥10% weight, 90% had MASH resolution, and 45% demonstrated fibrosis regression, with a dose-response relationship.21 A recent meta-analysis of 43 studies with 2,809 patients with MASLD reported that the degree of weight loss was independently associated with histological improvement. Every 1 kg of weight loss was associated with a 0.83-unit (p<0.001) reduction in alanine aminotransferase (ALT; U/L), a 0.56-unit (p<0.001) reduction in aspartate transaminase (AST; U/L), and a 0.77 percentage point (p<0.01) reduction in steatosis assessed by radiology and histology, indicating a graded therapeutic effect.22 Surgical intervention further confirms the impact of weight reduction. In a long-term follow-up study of patients who underwent bariatric surgery, 84% achieved MASH resolution without progression of fibrosis (odds ratio [OR], 0.84; 95% confidence interval [CI], 0.73 to 0.92).23 On the basis of these encouraging data, major academic societies, including the American Association for the Study of Liver Disease (AASLD), American Association of Clinical Endocrinology (AACE), European Association of the Study of the Liver (EASL) have recommended in their Practice Guidelines for MASLD that reduction of body weight by ≥3%–7% can improve steatosis, and reduction of body weight by ≥7%–10% can improve steatohepatitis and fibrosis.24 2. Physical activity and sedentary behavior Beyond weight loss alone, physical activity improves metabolic health and liver-related outcomes in MASLD. In contrast, sedentary behavior is an independent predictor of MASLD.25 A US population-based study demonstrated that physical activity ≥150 minutes per week is associated with significantly lower prevalence of MASLD (OR, 0.58; 95% CI, 0.53 to 0.64) compared to inactive individuals, with a clear dose-dependent response.26 A cross-sectional analysis of 667 participants noted that each 10-minute/day increase in total physical activity was associated with a 4.2% reduction in the odds of MASLD.27 A recent accelerometer-based population study reported that higher levels of physical activity are associated with reduced all-cause and cardiovascular mortality among individuals with MASLD.28 Regarding the type of physical activity, leisure-time and transportation-related physical activity exert a dose-dependent protective effect on MASLD.26 In a recent meta-analysis of 43 studies including 2,070 individuals with MASLD, combined aerobic plus resistance training ranked highest for improvements in triglycerides, total cholesterol, and low-density lipoprotein (LDL) cholesterol, while aerobic training ranked highest for ALT and high-density lipoprotein cholesterol, and resistance training ranked highest for AST improvement, suggesting that combined training may provide the broadest metabolic benefits in individuals with MASLD.29 Moreover, meeting recommended guidelines for leisure-time and transportation-related physical activity was associated with lower risks of all-cause and cardiovascular mortality in individuals with MASLD.30 Conversely, prolonged sedentary behavior was associated with a greater risk of MASLD. A cross-sectional study of 3,729 overweight/obese adults reported that prolonged sedentary behavior was associated with 43% increased odds of MASLD.31 Occupational activity may also influence the risk of MASLD. Occupation-related physical activity was not associated with MASLD and advanced fibrosis, although leisure-time physical activity was associated with MASLD26 and advanced fibrosis.32 However, recent studies suggest that prolonged working hours and occupational stress can contribute to the development of MASLD. In a population-based study, long working hours were associated with a higher risk of MASLD, with working more than 50 hours per week increasing the likelihood of MASLD by 57%.33 Occupational stress may further contribute, with individuals with increased work-related stress having a significantly higher risk of developing MASLD.34 As a result, most major guidelines from the AACE, AASLD, and EASL recommend increasing physical activity to 150–300 minutes/week of moderate intensity or 75–150 minutes/week of vigorous intensity, as well as resistance activity 2–3 days/week, alongside decreasing overall sedentary time.24 3. Dietary interventions Dietary quality and composition are modifiable determinants of MASLD progression. A US population-based study showed that higher diet quality was associated with progressively lower risk of developing MASLD (OR, 0.70; 95% CI, 0.50 to 0.98 for the highest vs the lowest diet quality).35 The overall benefits of dietary interventions appear to improve liver health. A 12-week randomized trial comparing dietary effects reported that the Mediterranean and low-fat diets significantly reduced hepatic steatosis (p<0.01) despite minimal differences in weight loss. The benefits of adherence to a Mediterranean diet were significantly greater than those of a low-fat diet (88% vs 64%; p=0.048), highlighting its long-term suitability in the setting of MASLD.36 Low-carbohydrate and ketogenic diets have yielded similar results, demonstrating reductions in liver fat, insulin resistance, and hepatic inflammation.37 Emerging evidence also supports the effectiveness of the Dietary Approaches to Stop Hypertension (DASH) diet. A 12-week randomized controlled trial involving 70 patients reported significant reductions in hepatic fibrosis and hepatic steatosis compared with the control group, along with improvements in aminotransferase levels.38 Furthermore, a randomized controlled trial comparing intermittent fasting, calorie restriction, and standard of care found that hepatic steatosis was significantly decreased in the intermittent fasting and calorie restriction groups compared to the standard of care group.39 Based on these findings, current major guidelines recommend caloric restriction of approximately 500–750 kcal,40 as well as the Mediterranean, low-fat, low-carbohydrate diets and intermittent fasting.24 4. Smoking Smoking is both an established and modifiable risk factor for MASLD. A meta-analysis of 19 studies including 450,130 individuals reported that smoking was significantly associated with an increased risk of MASLD (OR, 1.30; 95% CI, 1.21 to 1.40).41 Smoking promotes oxidative stress, inflammation, and metabolic damage, contributing to the development and progression of MASLD.42 Multiple studies have reported that smoking is a significant risk factor for MASLD. Importantly, smoking cessation appears to decrease the risk for MASLD. A cross-sectional study of 12,241 Korean men noted that current smokers had an increased risk of MASLD. However, the odds of MASLD decreased with longer duration of smoking cessation (<10 years vs 10–20 years and ≥20 years: OR, 0.75; 95% CI, 0.64 to 0.88; p<0.001 and OR, 0.75; 95% CI, 0.59 to 0.95; p=0.017, respectively).43 A recent study indicates that secondhand smoke exposure is associated with an increased prevalence of MASLD and significant fibrosis among adolescents.44 This finding suggests that preventing secondhand smoke exposure in this population could help reduce the burden of MASLD and significant hepatic fibrosis.44 5. Alcohol consumption In addition to tobacco exposure, alcohol consumption has also been shown to be a significant driver of the development and progression of MASLD. A longitudinal study of 8,727 individuals from the China Multi-Ethnic Cohort examined how changes in drinking levels were associated with the risk of MASLD. It was noted that sustained modest drinking (<140 g of alcohol/week for males, <70 g of alcohol/week for females) was associated with an increased risk of MASLD.45 A recent cohort study from Spain and the US reported that alcohol consumption was independently linked to significant fibrosis and at-risk MASH.46 A dose-response relationship was observed, with higher weekly alcohol consumption and a greater number of cardiometabolic criteria associated with increased prevalence of significant fibrosis and at-risk MASH.46 Of note, even low-to-moderate alcohol consumption was associated with an increased risk of disease severity in MASLD. Any level of alcohol consumption was associated with worsening of liver outcomes in individuals with MASLD, even when drinking within recommended limits.47 Therefore, there may be no safe level of alcohol intake in patients with MASLD.46 Furthermore, alcohol consumption was associated with the risk of cancer. A case-control study of 210 individuals reported that alcohol consumption increased the risk of HCC by 6-fold (OR, 5.7; 95% CI, 2.4 to 13.7).48 In a case-control study of 108 HCC cases and 108 matched controls, heavy alcohol consumption was associated with an approximately 5.5-fold increased risk of HCC (hazard ratio, 5.51; 95% CI, 2.39 to 12.7).49 Given increasing evidence that even moderate alcohol consumption increases the risk of MASLD progression, international guidelines advise alcohol restriction and abstinence, especially in advanced fibrosis and cirrhosis.50 PHARMACOLOGICAL THERAPY Although lifestyle modifications remain the first-line treatment for individuals with MASLD, sustained weight loss and behavioral changes are difficult to achieve and maintain. Consequently, pharmacologic therapies have emerged as an important addition, especially in patients with progressive liver disease. 1. Resmetirom Resmetirom was the first drug approved by the US FDA for the treatment of MASH with moderate to advanced fibrosis (F2–F3).16 Resmetirom is a selective THR-β agonist that modulates lipid metabolism genes, and thus increases hepatic fat metabolism, and reduces hepatic fat accumulation.51 A phase 3 trial in adults with biopsy-confirmed MASH and fibrosis stages F1B–F3 evaluated the effects of once-daily resmetirom at 80 mg and 100 mg compared with placebo.52 MASH resolution was achieved in 25.9% of the 80 mg group and 29.9% of the 100 mg group, compared with only 9.7% in the placebo group (p<0.001). Fibrosis improved by at least one stage in 24.2% of 80 mg-treated patients and 25.9% of 100 mg-treated patients, compared with only 14.2% in the placebo group. Cardiometabolic profiles were significantly improved, specifically LDL cholesterol levels in the treatment versus placebo group (80 mg, –13.6%; 100 mg, –16.3%; placebo, 0.1%; p<0.001), indicating a parallel reduction in cardiovascular risk.52 Notably, diarrhea and nausea were more frequent in the treatment group than in the placebo group.52 In a phase 2 MASH cohort, treatment with resmetirom was associated with significant and sustained improvements in physical health-related quality of life, especially among those who achieved ≥ 30% reduction in magnetic resonance imaging-proton density fat fraction (MRI-PDFF).53 A meta-analysis of 2,234 individuals with MASLD/MASH evaluated the efficacy of resmetirom on hepatic fat reduction and lipid profiles, as well as adverse side effects. Resmetirom treatment was associated with a significant reduction in MRI-PDFF when comparing 80 mg and 100 mg resmetirom to placebo.54 Treatment was also associated with significant improvements in LDL cholesterol, triglycerides, lipoproteins, and liver enzymes, with no major differences in the adverse effects.54 The AASLD Practice Guidelines outline the use of resmetirom in patients with MASH and moderate-to-advanced fibrosis (F2–F3).55 Patient selection and monitoring at 3, 6, and 12 months depend on noninvasive liver disease assessment using imaging. Treatment is 100 mg daily for patients ≥100 kg or 80 mg daily for those <100 kg. Continuation of resmetirom is supported by a ≥25% reduction in vibration-controlled transient elastography liver stiffness or a ≥20% reduction in magnetic resonance elastography liver stiffness, and by improvements in ALT. Resmetirom is not recommended in patients with cirrhosis, uncontrolled liver disease, excess alcohol consumption, or untreated thyroid disease.55 2. GLP-1 RAs and co-agonists The prevalence of MASLD is closely associated with T2DM. A meta-analysis of 123 studies (n=2,224,144) noted that the global pooled prevalence of MASLD among patients with T2DM was 65.3% (95% CI, 62.3% to 68.2%) with the prevalence of MASH, significant fibrosis, and advanced fibrosis at 66.4% (56.6% to 75.0%), 40.8% (24.2% to 59.7%), and 15.5% (7.0% to 30.9%), respectively.56 Given that insulin resistance is a major driver of hepatic steatosis and inflammation, medications for T2DM promoting insulin sensitivity have shown promising benefits in mitigating MASLD. Several GLP-1 receptor agonists (GLP-1 RAs) are approved for the treatment of T2DM, which have the additional benefit of reducing cardiovascular events.57 GLP-1 RAs mimic endogenous GLP-1, enhancing glycemic control in T2DM by stimulating insulin secretion, suppressing glucagon secretion, and slowing gastric emptying, thereby promoting weight loss. These effects collectively benefit MASLD by reducing hepatic steatosis, inflammation, and fibrosis.58 A recent meta-analysis including 25 randomized controlled trials with 2,600 patients treated with GLP-1 RAs for a median duration of 24 weeks demonstrated a 5.21% decrease in liver fat content and overall improvements in steatosis, hepatocellular ballooning, and inflammation.59 1) GLP-1 RAs (1) Semaglutide Semaglutide, a long-acting GLP-1 RA, has been extensively studied for its positive effects on the progression of MASLD and is now approved by the FDA for the treatment of MASH.17 In a phase 2, randomized, placebo-controlled trial, 320 individuals with biopsy-proven MASH were treated with once-daily semaglutide at 0.1, 0.2, or 0.4 mg or placebo for 72 weeks.60 MASH resolution occurred in 59% of patients receiving 0.4 mg of semaglutide, compared with 17% receiving placebo (p<0.001), with an OR of 6.87 (95% CI, 2.60 to 17.63; p<0.001). However, improvements in fibrosis were noted to be insignificant (95% CI, 0.62 to 3.28; p=0.48).60 Recently, interim results from an ongoing phase 3 randomized trial evaluated once-weekly subcutaneous semaglutide 2.4 mg compared to placebo in patients with MASH and F2–F3 fibrosis.61 At 72 weeks, MASH resolution was achieved in 62.9% of semaglutide-treated patients compared to 34.3% in the placebo group (95% CI, 21.1 to 36.2; p<0.001). Importantly, these results also showed a significant reduction in liver fibrosis with semaglutide (36.8%) compared with placebo (22.4%) (95% CI, 7.5 to 21.3; p<0.001), suggesting concurrent benefits for MASH resolution and fibrosis improvement.61 A prospective proteomic analysis utilizing data from the STEP 1 and STEP 2 trials found that treatment with semaglutide 2.4 mg was associated with an approximately 5-fold improvement in MASLD profiles, supporting the therapeutic effect of semaglutide in patients with MASH.62-64 However, the beneficial effects of semaglutide seem to be reduced in more advanced disease. A placebo-controlled phase 2 trial of MASH patients across 38 centers in Europe and the US found that semaglutide 2.4 mg in patients with compensated MASH cirrhosis did not significantly improve fibrosis (p=0.087) or MASH resolution (p=0.29).65 (2) Liraglutide Liraglutide has been investigated in several trials for its effects on patients with MASLD and concurrent obesity and T2DM. Evidence of liraglutide’s effects on liver histology comes from the LEAN trial, a multicenter, placebo-controlled phase 2 trial conducted across four UK medical centers.66 Once-daily liraglutide (1.8 mg) was assessed in overweight patients with clinical evidence of MASLD. After 48 weeks of treatment, 39% of patients receiving liraglutide had resolution of MASH, compared with 9% in the placebo group (relative risk [RR], 4.3; 95% CI, 1.0 to 17.7; p=0.019). Additionally, progression of fibrosis occurred less frequently in the liraglutide than in the placebo group (9% vs 36%: RR, 0.2; 95% CI, 0.1 to 1.0; p=0.04). While reported adverse effects were generally mild, diarrhea, constipation, and loss of appetite were more common in the liraglutide-treated group.66 Imaging-based studies have shown mixed effects of liraglutide, particularly in patients with T2DM.67 In a randomized trial comparing insulin glargine and liraglutide, insulin improved glycated hemoglobin (HbA1c) (7.9% to 7.2%; p=0.005), reduced liver MRI-PDFF (13.8% to 10.6%; p=0.005), and lowered total liver fat index (304.4%·mL vs. 209.3%·mL; p=0.01). Liraglutide improved HbA1c (7.6% to 6.7%; p<0.001) but had no significant effect on liver MRI-PDFF (p=0.15) or total liver fat index (p=0.39).67 However, subsequent studies with larger cohorts and longer treatment durations have demonstrated favorable hepatic outcomes. A prospective study in patients with uncontrolled T2DM found that treatment with liraglutide 1.2 mg/day reduced liver fat content by 31% (p<0.001), alongside significant decreases in triglyceride levels (p=0.019) and HbA1c (p=0.034), implying that its effects may depend on treatment duration and disease severity.68 A randomized study found that discontinuation of liraglutide after 26 weeks led to significant weight regain (1.8±2.1 kg) and increased liver fat fraction (4.0%±5.3%) compared to patients who underwent lifestyle modifications followed by weight maintenance, indicating the need to combine pharmacologic therapeutics with lifestyle modifications.69 The sustained benefit of liraglutide on MASLD appears to rely on ongoing treatment with lifestyle modifications, rather than short-term use alone. A study of women with MASLD and prior gestational diabetes further reinforces the effect of liraglutide in reducing hepatic steatosis in specific population cohorts. Treatment with liraglutide in this population reduced intrahepatic fat content and steatosis; however, it did not eliminate the presence of MASLD.70 (3) Dulaglutide Although there is limited research on dulaglutide, an extremely long-acting GLP-1 RA, in MASLD, clinical studies indicate hepatic benefits comparable to those of other GLP-1 RAs. In a 24-week open-label, randomized trial of 64 patients with T2DM and liver fat content ≥6.0%, once-weekly dulaglutide led to a significant relative liver fat reduction of 26.4% (95% CI, –44.2% to –8.6%; p=0.004), an approximately 2.6-fold greater reduction compared to usual care.71 Dulaglutide treatment also significantly lowered γ-glutamyl transpeptidase (GGT) levels (p=0.025), while changes in aminotransferases did not reach statistical significance.71 However, a post hoc analysis of 1,499 participants from the AWARD clinical trial found that dulaglutide significantly reduced ALT, AST, and GGT compared to placebo. Reductions in ALT were more pronounced in the MASLD/MASH subgroup compared to the overall cohort (–8.8 U/L vs –6.7 U/L).72 A recent prospective study of patients with T2DM and MASLD treated with dulaglutide 1.5 mg weekly for 3 months found an 8.6% reduction in liver fat content, as well as an 18.7% decrease in HbA1c and 7.29% weight loss.73 However, interpretation of these findings is limited due to the absence of a placebo or control group. 2) Co-agonists Glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor co-agonists are a new generation of incretin-based therapies used for treatment in T2DM and obesity, with emerging evidence suggesting concomitant effects on MASLD.74,75 (1) Tirzepatide Tirzepatide has been shown to improve histologic, imaging, and biomarker outcomes in MASLD/MASH across multiple studies. In the phase 2 multicenter placebo-controlled SYNERGY-NASH trial, 190 participants with biopsy-confirmed MASH and stage F2 or F3 fibrosis were treated with tirzepatide at 5 mg, 10 mg, or 15 mg weekly or with placebo for 52 weeks. Resolution of MASH was achieved in 44% of participants receiving 5 mg, 56% receiving 10 mg, and 62% receiving 15 mg, respectively. Similarly, improvements of at least one fibrosis stage were observed across all tirzepatide groups compared to placebo (difference vs placebo: 5 mg, 25% [95% CI, 5% to 46%]; 10 mg, 22% [95% CI, 1% to 42%]; and 15 mg, 21% [95% CI, 1%–42%]).76 Further evidence comes from imaging-based evidence from the phase 3 SURPASS-3 trial of 502 participants with T2DM showed that tirzepatide 10 mg and 15 mg resulted in significantly greater reductions in liver fat content at week 52 compared to insulin degludec, with an estimated treatment difference of −4.71% (95% CI, −6.72% to −2.70%; p<0.001).77 A post hoc analysis found that tirzepatide produced dose-dependent reductions in ALT, with the 10 mg and 15 mg doses achieving an additional –6.8 U/L (95% CI, –11.8 to –1.8; p=0.008) and –6.4 U/L (95% CI, –11.7 to –1.1; p=0.018), respectively, compared to dulaglutide 1.5 mg. Compared with placebo, tirzepatide was also associated with significant reductions in keratin-18 and procollagen III, with significant increases in adiponectin, supporting tirzepatide’s beneficial effects on mitigating hepatocellular injury and fibrogenesis.74 In addition, researchers evaluating the synergistic effect of tirzepatide and diet modification compared a low-energy ketogenic therapy to a low-calorie diet. While both diets in combination with tirzepatide led to significant reductions in body weight, reductions in hepatic steatosis and stiffness were significantly greater in the low-energy ketogenic therapy group (controlled attenuation parameter [CAP]: –12.5%, p<0.001; liver stiffness measurement [LSM]: –22.7%, p<0.001) compared to the low-calorie diet group (CAP: –6.7%, p=0.014; LSM: –9.2%, p=0.022).78 (2) Survodutide While research on survodutide, a dual agonist of glucagon and GLP-1 receptors, remains limited, early evidence suggests that it may modulate MASLD progression, particularly in advanced disease. In a 48-week phase 2 randomized trial of 293 individuals with MASH and fibrosis stages F1–F3, participants received survodutide at doses of 2.4 mg, 4.8 mg, or 6.0 mg or placebo weekly.79 Improvements in MASH were observed in 47%, 62%, and 43% of participants in the 2.4 mg, 4.8 mg, and 6.0 mg groups, respectively, compared with 14% in the placebo group (p<0.001). A decrease in liver fat content by at least 30% occurred in 63%, 67%, and 57% of participants receiving survodutide, respectively, versus 14% in the placebo group. Improvements in fibrosis by at least one stage were observed in 34%, 36%, and 34% of survodutide-treated participants, compared with 22% in the placebo group. Adverse events in the survodutide-treated group were nausea, diarrhea, and vomiting.79 Evidence of survodutide having beneficial effects in more advanced MASLD comes from a phase 1 multinational trial of 82 participants with Child-Pugh class A, B, or C cirrhosis, as well as individuals without cirrhosis. Participants initiated survodutide at 0.3 mg weekly, with dose escalation to 6.0 mg over 28 weeks. Substantial reductions in liver fat by MRI-PDFF were observed in participants without cirrhosis (–43.29%) and those with Child-Pugh A cirrhosis (–51.59%), whereas minimal change was seen in those with Child-Pugh B cirrhosis (–0.48%), consistent with reduced steatosis in advanced disease. Importantly, despite limited changes in liver fat in Child-Pugh B patients, markers of fibrosis and fibrogenesis improved across cirrhotic cohorts, including reductions in liver stiffness by magnetic resonance elastography (–0.13 kPa, –1.12 kPa, –1.02 kPa, respectively), enhanced liver fibrosis (ELF) scores (–0.149, –0.369, –0.522, respectively), and plasma Pro-C3 levels (–35.79%, –22.59%, –22.67%, respectively). Liver enzymes were also generally reduced across cohorts.80 3. SGLT2 inhibitors Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a class of drugs that act in the kidney to prevent the reabsorption of excess glucose and are the mainstay treatments for T2DM, providing additional cardiovascular and renal protection.81 Recent trials demonstrate that SGLT2 inhibitors may have beneficial effects on both early and more severe MASLD. 1) Empagliflozin In a randomized, phase 4, placebo-controlled trial, 84 patients with well-controlled T2DM were treated with 25 mg of empagliflozin daily.82 After 24 weeks, the treatment group had a relative reduction in liver fat of 22% (95% CI, –36% to –7%; p=0.009), corresponding to a 2.3-fold greater reduction than placebo. Treatment was also associated with improvements in uric acid and adiponectin, suggesting a potential role for empagliflozin in the early treatment of MASLD in patients with T2DM.82 Similar reductions in liver fat content were observed in a separate randomized trial including patients with and without T2DM, indicating hepatic effects of empagliflozin may be independent of glycemic levels.83 In another placebo-controlled trial, patients with MASLD received empagliflozin (10 mg/day) or a placebo for 24 weeks.84 In those treated with empagliflozin, liver stiffness (6.03±1.40 to 5.33±1.08 kPa; p=0.001) and hepatic steatosis (37.2% vs 17%; p=0.035) showed significant improvements compared to placebo. Additionally, significant decreases in AST, ALT, and insulin levels were observed in the treatment group.84 In line with these findings, another trial of MASLD patients without T2DM showed greater reductions in liver fat in the empagliflozin-treated group than in the placebo group (–2.49% vs –1.43%; p=0.025).85 To assess patients with both MASLD and T2DM, Chehrehgosha et al.86 evaluated the efficacy of empagliflozin (10 mg) and pioglitazone (30 mg) compared to placebo for 24 weeks. Compared to pioglitazone, empagliflozin treatment resulted in greater reductions in liver stiffness (–0.77 kPa [95% CI, –1.45 to –0.09; p=0.02] vs 0.01 kPa [95% CI, –0.70 to 0.71; p=0.98]; p for comparison=0.03). Empagliflozin significantly reduced body weight (p<0.001), whereas weight increased in both the placebo and pioglitazone groups.86 A recent 2025 phase 2 trial of 119 patients with MASLD and T2DM treated with empagliflozin (10 mg or 25 mg daily) or standard care for 6 months found that empagliflozin led to significant improvements in aminotransferase, fibrosis indices, and liver fat content, with 100% of treated patients achieving grade 0 steatosis on MRI, compared with placebo.87 2) Dapagliflozin In a multicenter, randomized, placebo-controlled trial of 154 adults with biopsy-proven MASH with or without T2DM, the effects of dapagliflozin (10 mg daily) on MASH and fibrosis were evaluated.88 After 48 weeks, 23% of patients in the dapagliflozin group had MASH resolution compared to 8% in the placebo group, with a risk ratio of 2.91 (95% CI, 1.22 to 6.97; p=0.01). Improvements in fibrosis were achieved in 45% of participants in the dapagliflozin group, compared to 20% in the placebo group (risk ratio, 2.25; 95% CI, 1.35 to 3.75; p=0.001).88 Consistent with these findings, a placebo-controlled trial of patients with T2DM demonstrated that treatment with dapagliflozin (10 mg daily for 8 weeks) resulted in significantly reduced liver fat content, measured by MRI-PDFF (–3.74%, p<0.01), as well as reductions in liver volume (–0.10 L, p<0.05).89 We summarized the mechanisms of action, clinical trial outcomes, and side effects of THR-β agonists, GLP-1 RAs and co-agonists, and SGLT2 inhibitors, as mentioned above, in Table 1. 4. PPAR agonists 1) Pioglitazone Pioglitazone, a thiazolidinedione and peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist, is a widely used antidiabetic therapy with significant evidence suggesting its efficacy in MASLD, particularly in individuals with insulin resistance and T2DM. In a randomized trial of 101 individuals with biopsy-proven MASH and either prediabetes or T2DM, participants were prescribed a hypocaloric diet and assigned to pioglitazone 45 mg/day or placebo for 18 months.90 Pioglitazone treatment led to resolution of NASH in 51% of patients, with a 32% difference from placebo (95% CI, 13% to 51%; p<0.001). Significant improvements were also observed in fibrosis scores (treatment difference, –0.5; 95% CI, –0.9 to 0.0; p=0.039), hepatic triglyceride content (reduction from 19% to 7%, treatment difference –7 percentage points; 95% CI, –10 to –4; p<0.001), and adipose tissue, hepatic, and skeletal muscle insulin sensitivity (p<0.001 for all vs placebo). While adverse event rates did not differ significantly between treatment and placebo, weight gain was greater with pioglitazone (mean +2.5 kg vs placebo).90 Following analyses comparing results in patients with and without T2DM found that while pioglitazone was effective in both prediabetes and T2DM, patients with T2DM experienced significantly greater reductions in liver fibrosis (p=0.035) and greater improvements in insulin sensitivity (p<0.001), suggesting greater therapeutic potential in more advanced diabetes.91 Evidence further indicates that pioglitazone is efficacious at lower doses. In a clinical study of patients with T2DM receiving pioglitazone at an average dose of 26 mg/day, significant improvements in liver steatosis, liver inflammation, and insulin sensitivity were observed. Measures of liver fat and inflammation were improved with pioglitazone vs. sulfonylureas across all treatment groups. Insulin resistance also decreased more with pioglitazone than with sulfonylureas.92 However, pioglitazone frequently causes weight gain and fluid retention, which can precipitate or worsen heart failure, increase fracture risk, etc. Therefore, individualized risk–benefit discussion and close monitoring of weight, edema, and cardiac status are needed for long-term use. A more recent 2025 study found synergistic effects of pioglitazone and empagliflozin (SGLT2 inhibitor). In a randomized controlled trial, 50 participants with T2DM and MASLD were assigned pioglitazone (15 mg), empagliflozin (10 mg), or a combination (pioglitazone 15 mg and empagliflozin 10 mg) daily for 24 weeks.93 Combination therapy resulted in the largest reductions in liver fat ≥30% and stiffness ≥20% (50.0% for combination therapy vs 21.4% with pioglitazone and 6.3% with empagliflozin; p=0.029).93 Long-term benefits of pioglitazone were observed in a multicenter retrospective study that stratified patients by treatment duration (1–3 years vs 4–10 years). Treatment with pioglitazone resulted in significant reductions in liver enzymes (ALT and GGT) and FibroScan-AST scores (1–3 years, p=0.042; 4–10 years, p=0.012). However, liver steatosis, as assessed by CAP, was significantly decreased only in the 4–10-year group (p=0.002), suggesting sustained metabolic and hepatic benefits with long-term pioglitazone therapy.94 2) Lanifibranor Lanifibranor, a pan-PPAR-α/δ/γ agonist, targets multiple MASLD pathways, improving β-oxidation and fatty acid oxidation, increasing adiponectin levels, improving insulin sensitivity, and reducing hepatic triglyceride accumulation. By downregulation of metabolic and inflammatory pathways, lanifibranor reduces steatosis, hepatic inflammation, and fibrosis in MASLD.95 In a phase 2 placebo-controlled trial of 247 patients with MASH, a daily dose of 1,200 mg or 800 mg of lanifibranor or placebo was administered for 24 weeks.96 Those who received the 1,200 mg dose had a significantly greater reduction in hepatic steatosis, ballooning, and inflammation compared with the placebo group (1,200 mg vs placebo, 55% vs 33%; p=0.007). Additionally, resolution of MASH in the 1,200 mg dose, 800 mg dose, and placebo was 49%, 39% and 22%, respectively (RR for a response in the 1,200 mg lanifibranor group vs the placebo group: 2.2 [95% CI, 1.5 to 3.3] and RR in the 800 mg vs placebo: 1.7 [95% CI, 1.1 to 2.7]). Liver enzyme levels decreased, and lipid, inflammatory, and fibrosis biomarkers were found to improve in the lanifibranor groups. However, side effects such as diarrhea, nausea, peripheral edema, anemia, and weight gain occurred more frequently with lanifibranor compared to the placebo.96 Additional metabolic benefits from a phase 2 study of 38 patients with MASLD and T2DM were observed.97 Treatment with lanifibranor 800 mg daily significantly reduced liver fat content compared with placebo (relative change in intrahepatic triglyceride content: –44% vs –12%: least squares mean difference, –31%; 95% CI, –51% to –12%; p=0.002) and was associated with improvements in both hepatic and peripheral insulin sensitivity. Despite this, treatment with lanifibranor was associated with weight gain (+2.7% vs −1.0%).97 5. FGF21 analogs Fibroblast growth factor 21 (FGF21) is an endogenous stress hormone that regulates lipid and glucose metabolism, potentially reducing fat via the AMPK pathway, which stimulates fatty acid oxidation and decreases lipogenesis. Additionally, FGF21 mitigates triglyceride accumulation, improves insulin sensitivity, and increases lipoprotein receptor expression.98 1) Pegozafermin Pegozafermin is a glycopegylated recombinant analog of FGF21 with an increased half-life. In a phase 2 randomized, placebo-controlled trial, patients with biopsy-confirmed MASH and fibrosis stage F2 or F3 received pegozafermin at doses of 15 mg or 30 mg weekly, 44 mg every 2 weeks, or placebo.99 At week 24, improvements in fibrosis by at least one stage was seen in 27% of patients receiving pegozafermin 44 mg (difference vs placebo: 20 percentage points; 95% CI, 5 to 35; p=0.008), 26% with 30 mg (difference, 19 percentage points; 95% CI, 5 to 32; p=0.009), and 22% with 15 mg (difference, 14 percentage points; 95% CI, –9 to 38), compared with 7% on placebo.99 Additionally, resolution of MASH occurred in 26% of the 44 mg group (difference, 24 percentage points; 95% CI, 10 to 37), 23% of the 30 mg group (difference, 21 percentage points; 95% CI, 9 to 33), 37% of the 15 mg group (difference, 35 percentage points; 95% CI, 10 to 59), versus 2% in the placebo group.99 Histologic benefit was also demonstrated in the earlier phase 1b/2a trial, in which patients received pegozafermin at 27 mg/week for 20 weeks. Liver fat content, measured by MRI-PDFF, was found to decrease by 64.7% from baseline, accompanied by significant improvements in serum aminotransferases, non-invasive fibrosis markers, lipid profile, glycemic control, and body weight.100 Treatment was generally well tolerated, with mild/moderate adverse events, most commonly nausea and diarrhea, as well as increased appetite, reported more frequently in the pegozafermin group.100,101 2) Efruxifermin In the phase 2a randomized, double-blind, placebo-controlled trial, patients with MASH received efruxifermin 28 mg, 50 mg, 70 mg, or placebo.102 The primary endpoint, reductions in hepatic fat fraction measured by MRI-PDFF, was met across all treatment groups, with absolute changes of –12.3%, –13.4%, and –14.1% in the 28, 50, and 70 mg groups, respectively, versus 0.3% in the placebo (p<0.001). Adverse events were common but mostly mild, with gastrointestinal symptoms most frequently reported.102 Extension of this study demonstrated clinically significant antifibrotic effects. At 24 weeks, an improvement of at least one stage of fibrosis was observed in 20% of patients receiving placebo, compared with 39% in the efruxifermin 28 mg group and 41% in the 50 mg group (RR, 2.2; 95% CI, 1.0 to 5.0; p=0.036).103 In patients with more advanced disease, a study of 30 patients with MASH and stage 4 fibrosis showed significant improvements in fibrosis profiles. Efruxifermin treatment resulted in significant reductions in Pro-C3 (least-squares mean change from baseline: –9 μg/L vs –3.4 μg/L with placebo; p=0.013) and ELF scores (–0.4 vs +0.4; p=0.0036), and a decrease in liver stiffness that did not reach statistical significance. Thirty-three percent of patients achieved improvements in fibrosis by at least one stage, and 25% achieved resolution of MASH.104 These findings were further investigated in a phase 2b trial (n=181) with compensated cirrhosis. At 36 weeks, efruxifermin did not show statistically significant improvements in fibrosis compared with placebo. However, at 96 weeks, the 50 mg dose was associated with a statistically significant reduction in fibrosis (difference from placebo, 16 percentage points; 95% CI, 2 to 30).105 Consistent with these results, another randomized, placebo-controlled trial of 128 participants demonstrated that at 96 weeks, only the 50 mg efruxifermin dose achieved statistically significant fibrosis improvements compared with placebo, with a difference of +31 percentage points (95% CI, 12 to 49; p=0.003).106 A double-blind, placebo-controlled, phase 2b study in patients with T2DM and MASH evaluating efruxifermin in combination with a GLP-1 RA found that treatment reduced hepatic fat fraction by 65% compared to a 10% reduction with GLP-1 treatment alone (p<0.001 vs placebo). Improvements were also observed in markers of liver injury, fibrosis, glucose, and lipid metabolism.107 3) Pegbelfermin While the efficacy of pegbelfermin has been investigated in clinical trials, a phase 2b trial found that pegbelfermin did not meet the primary endpoint, with no significant improvements in liver stiffness and steatosis; however, decreases in fibrogenesis-associated markers were observed.108-111 4) Aldafermin Aldafermin is an engineered variant of FGF19, an endocrine gastrointestinal hormone involved in the regulation of bile acid synthesis, carbohydrate metabolism, and energy homeostasis, and known to exert insulin-like metabolic effects. Through these mechanisms, aldafermin has demonstrated therapeutic potential to mitigate MASLD progression.112 In a randomized, placebo-controlled phase 2 trial, 82 patients with biopsy-confirmed MASH were assigned to receive aldafermin at doses of 3 mg or 6 mg daily or placebo for 12 weeks.112 Treatment with aldafermin resulted in rapid reductions in liver fat content, with 74% of patients in the 3 mg group and 79% in the 6 mg group achieving at least a 5% reduction in liver fat content from baseline, compared to 7% in the placebo group (RR, 10.0; 95% CI, 2.6 to 38.7 and RR, 11.4; 95% CI, 3.0 to 43.8, respectively; p<0.0001 for both comparisons). Adverse events, including injection-site reactions and gastrointestinal disturbances, were more frequent in the treatment group, though the majority were mild in severity. These results indicate aldafermin’s potential to rapidly reduce hepatic steatosis.112 A subsequent study evaluated histological improvements following aldafermin treatment. Participants were treated with aldafermin 1 mg, 3 mg, or placebo daily for 12 weeks. Treatment significantly reduced NAFLD activity scores (NAS) in both treatment groups (NAS, –1.9; 95% CI, –2.6 to –1.2; p<0.001 in the 1 mg group; NAS, –2.2; 95% CI, –3.1 to –1.3; p<0.001 in the 3 mg group). Fibrosis scores improved in the 3 mg group (–0.5; 95% CI, –0.9 to 0; p=0.035). Significant reductions were observed in serum aminotransferases and fibrogenesis markers, including Pro-C3 and ELF score.113 Of importance, evaluation of dose-dependent fibrosis effects in a randomized, placebo-controlled trial found that while higher proportions of patients receiving aldafermin 0.3 and 3.0 mg achieved ≥1 stage fibrosis improvement, these differences were not statistically significant, and the trial did not demonstrate a dose-dependent response relationship.114 However, more favorable results were observed in patients with more advanced diseases. A multicenter, placebo-controlled phase 2b trial of 160 patients with compensated MASH cirrhosis received aldafermin 0.3 mg, 1 mg, 3 mg, or placebo for 48 weeks found that the 3 mg group had significant reductions in ELF scores compared to placebo (95% CI, –0.7 to –0.2; p=0.0003).115 Dose-dependent reductions in aminotransferases were observed (LSM differences in ALT of –13.5 U/L and –17.0 U/L in the 1 mg and 3 mg groups, respectively, and AST reductions of –7.3 U/L and –11.6 U/L; p<0.001 for all comparisons). Significant decreases in Pro-C3 were found in the 1 mg and 3 mg groups (p=0.017 and p=0.0034 vs placebo, respectively). Liver stiffness declined by 30.1% with aldafermin treatment in the 1 mg group (p=0.036) and by 21.3% in the 3 mg group; this difference was not significant (p=0.12).115 6. FXR agonists 1) Obeticholic acid Obeticholic acid is a selective farnesoid X receptor (FXR) agonist. FXR plays a critical role in metabolism and bile acid regulation and has been evaluated for its antifibrotic effects in patients with MASLD/MASH.116 In a phase 3 multicenter, randomized, placebo-controlled trial, 931 patients with biopsy-confirmed MASH and stage F2-F3 fibrosis were assigned to obeticholic acid 10 mg, obeticholic acid 25 mg, or placebo for 18 months.117 The primary endpoint of greater than one-stage improvement in fibrosis without worsening of MASH was achieved in 22.4% of patients receiving obeticholic acid 25 mg compared with 9.6% in the placebo group (p<0.0001). Although a higher proportion of patients treated with obeticholic acid 25 mg achieved MASH resolution, the difference did not reach statistical significance (6.5% vs 3.5%; p=0.093).117 There remain key issues regarding dose-dependent pruritus, which have limited its tolerability.118 In addition, obeticholic acid is associated with adverse lipid effects. In a study of 196 patients evaluating lipoprotein profiles, total LDL particle concentration increased after 12 weeks of obeticholic acid therapy compared with placebo (p<0.001), with levels reverting to baseline after drug discontinuation.119 The FDA declined conditional approval for obeticholic acid because its overall benefit–to–risk profile was considered unfavorable, with a notably high proportion of dyslipidemia and pruritus, contributing to the decision to halt its development for MASH. 2) Cilofexor Cilofexor, a nonsteroidal FXR agonist, has been evaluated in several phase 2 trials for its effects on disease activity in MASLD/MASH. In a placebo-controlled phase 2 trial of 140 patients with biopsy-confirmed MASH, participants received cilofexor (30 mg or 100 mg) or placebo for 24 weeks.120 Treatment with cilofexor resulted in significant reductions in liver fat content, with a median relative decrease in MRI-PDFF of –22.7% compared with an increase of +1.9% observed with placebo (p=0.003). While significant reductions in GGT and markers of bile acid synthesis were observed, no significant improvements were observed in measurements of liver stiffness or aminotransferase levels.120 Recently, the potential role of cilofexor in combination therapy has been investigated. In a phase 2b trial of 392 patients with fibrosis (F3–F4), participants received cilofexor (30 mg), firsocostat (20 mg), or selonsertib (18 mg), as either monotherapy or in a two-drug combination for 48 weeks. While cilofexor monotherapy conferred no significant improvements in fibrosis stage, MASH resolution, hepatic steatosis, or liver profiles, patients receiving cilofexor/firsocostat combination were more likely to achieve a ≥2-point improvement in NAS (35% vs 11%; p=0.002), ≥1-grade improvements in steatosis (26% vs 6%; p=0.009), lobular inflammation (57% vs 29%; p=0.004), and hepatocellular ballooning (29% vs 13%; p=0.04), compared to placebo.121 Another investigation evaluated cilofexor in combination with semaglutide. In a 24-week randomized study of patients with MASH, treatment with semaglutide with cilofexor 30 mg resulted in a significantly greater reduction in hepatic steatosis, as assessed by CAP, compared to semaglutide monotherapy (p=0.038). Significant reductions in ALT were also observed in the combination group (p<0.05). However, no significant differences were observed in MRI-PDFF, fibrosis markers, or liver stiffness, indicating limited benefits on fibrosis endpoints.122 We summarized the mechanisms of action, clinical trial outcomes, and side effects of PPAR agonists, FGF21 agonists, and FXR agonists, as mentioned above, in Table 2. 7. Tailoring therapeutic strategies to MASH phenotypes As the therapeutic landscape of MASH expands, selecting the most appropriate therapy becomes increasingly complex. Therapeutics for MASLD should be personalized and guided by the underlying drivers of disease, including the extent of metabolic dysfunction, comorbidities such as T2DM and obesity, and the stage of hepatic fibrosis. In general, current therapies can be divided into those targeting systemic metabolic dysfunction and those directly targeting hepatic steatosis and fibrosis. Some major drug classes were categorized, contrasting the direct, liver-focused acceleration of fat metabolism by THR-β agonists with the powerful systemic metabolic reset and profound weight loss driven by GLP-1 RAs, and considering the balanced approach of PPAR agonists. Systemic therapies such as GLP-1 RAs and GIP/GLP-1 co-agonists are highly advantageous for individuals with obesity and T2DM, as they improve insulin sensitivity, facilitate substantial weight loss, and reduce hepatic fat. In contrast, liver-targeted therapies such as THR-β agonists and FGF21 analogs demonstrate potent anti-steatotic and anti-fibrotic properties, making them a valuable choice, especially for patients with significant fibrosis. The management of advanced disease is difficult due to restricted therapeutic effectiveness, diminished tolerance to treatments, and a significant burden of comorbidities. Current treatment is driven by complications rather than by disease-modifying effects. Future research should focus on further characterizing the effects of current and emerging therapeutics on advanced disease while improving risk stratification to mitigate disease progression. Given the heterogeneity of MASLD, an individualized treatment approach and combination therapeutic strategies targeting multiple pathways are likely to play an increasingly important role in disease management. CONCLUSIONS MASLD is a growing global burden paralleled by obesity, T2DM, and cardiometabolic disease. Lifestyle modifications, including dietary restriction and physical activity, along with weight loss, constitute the cornerstone of managing MASLD. The considerable morbidity and mortality associated with MASLD highlight the necessity for pharmacologic therapies. The recent FDA approvals of resmetirom and semaglutide for the treatment of MASH with fibrosis have established a pharmacological strategy for managing MASH and fibrosis. Pharmacologic agents approved for T2DM, obesity, and cardiometabolic disease, such as GLP-1 RAs, GIP/GLP-1 receptor co-agonists, SGLT2 inhibitors, and PPAR agonists, are increasingly acknowledged for their substantial impact on MASH, alongside reductions in body weight, insulin resistance, and cardiovascular risk. Novel therapies, including FGF21 analogs, represent a new class of treatments that directly target the etiology of MASLD. Future therapeutic trials must encompass comprehensive, long-term outcome studies, evaluation of the benefits of multisystem illness care, and the development of combination techniques.